Quantcast
Last updated on April 19, 2014 at 13:20 EDT

Latest Ranibizumab Stories

2014-03-24 12:30:49

LONDON, March 24, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Analysis of the US Retinal Therapeutics Market Improvements in Administration and Efficacy Drive GrowthSince the introduction of Lucentis in 2006, vascular endothelial growth factor (VEGF) antagonists have become the clear choice in treatment for age related macular degeneration, diabetic macular edema, and retinal vein occlusion due to their high efficacy and safety. This research...

2014-03-12 12:29:13

Surveyed U.S. Payers Look for Substantial Delivery Achievements for Inclusion of New Agents in Formularies, According to Findings from Decision Resources Group BURLINGTON, Mass., March 12, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. and European retinal specialists ascribe a moderate to high unmet need for wet age-related macular degeneration (AMD) therapies that improve visual acuity. In line with this finding, surveyed U.S. retinal specialists expect that they...

2014-03-11 16:26:30

INCLINE VILLAGE, Nev., March 11, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the first quarter ending March 31, 2014, of approximately $133 million, as compared with actual revenue of $91.8 million for the first quarter of 2013, an approximate 45 percent increase. The forecasted growth in revenues is driven by increased fourth quarter 2013 sales for Avastin(®), Herceptin(®), Xolair(®), Kadcyla(®), Perjeta(®), and...

2014-03-05 08:28:36

VANCOUVER, March 5, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or "the Company") (TSX-V: ICO) (OTCQX: ICOTF) has announced the final month eight patient visit in the iDEAL Study. This US Phase 2 investigator-sponsored study is evaluating the efficacy and safety of iCo-007 after repeated injections in patients with Diabetic Macular Edema (DME). The study's primary endpoint is change in visual acuity from baseline to month eight, followed by secondary endpoints at month...

2014-02-03 08:27:04

INCLINE VILLAGE, Nev., Feb. 3, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that it has entered into an agreement with Genentech, Inc. (Genentech) and F. Hoffmann-La Roche Ltd. (Roche) which resolves all outstanding legal disputes between the parties, including its Nevada litigation with Genentech and Roche and its arbitration proceedings with Genentech related to the audit of royalties on sales. (Logo:...

2014-01-22 12:26:53

LONDON, Jan. 22, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report: Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need RemainsMacular Degeneration Therapeutics Market in Asia-Pacific to 2019 - Existing Angiogenics Retain Dominance Though High Unmet Need Remains SummaryGBI Research has released its research, "Macular Degeneration Therapeutics Market in Asia-Pacific to 2019 -...

2014-01-22 08:28:34

Patent Provides Coverage for Lpath's Anti-S1P Antibody in the Treatment of a Wide Variety of Ocular Disorders, Including Wet AMD SAN DIEGO, Jan. 22, 2014 /PRNewswire/ -- Lpath, Inc. (NASDAQ: LPTN), the industry leader in bioactive lipid-targeted therapeutics, received official notification from the U.S. Patent and Trademark Office that the company has been issued another key patent supporting its iSONEP(TM) program. The newly issued U.S. patent, No. 8,614,103, is entitled,...

2013-12-10 16:24:54

INCLINE VILLAGE, Nev., Dec. 10, 2013 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced revenue guidance for the fourth quarter ending December 31, 2013, of approximately $109 million, as compared with actual revenue of $86 million for the fourth quarter of 2012, an approximate 27 percent increase. (Logo: http://photos.prnewswire.com/prnh/20110822/SF55808LOGO) The forecasted growth in revenues is driven by increased third quarter 2013 sales for Avastin(®),...

2013-10-31 23:29:18

ResearchMoz include new market research report "Asia-Pacific Macular Degeneration Therapeutics Market to 2019: Industry Analysis, Size, Share, Growth, Trends And Forecast" to its huge collection of research reports. Click Here For Download Detail Report - http://www.researchmoz.us/macular-degeneration-therapeutics-market-in-asia-pacific-to-2019-existing-angiogenics-retain-dominance-though-high-unmet-need-remains-report.html Albany, NY (PRWEB) October 31, 2013 Macular...

2013-10-17 08:30:27

Novartis's Lucentis Remains the Most Preferred Intravitreal Pharmacotherapy for Wet AMD Across the EU5, According to a New Report from BioTrends Research Group EXTON, Pa., Oct. 17, 2013 /PRNewswire/ -- BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that, eight months after the approval of Bayer's Eylea for the treatment of wet age-related macular degeneration (AMD), nearly half of surveyed retinal...